Biodexa Pharmaceuticals has enrolled the 100th patient in its registrational Phase 3 trial of eRapa for Familial Adenomatous Polyposis (FAP), branded as Serenta. The trial is recruiting at 29 sites across the US and Europe, with two additional Canadian sites expected to open soon. Based on current Progression Free Survival event accrual, the pre-specified futility analysis may occur early next year, and database lock could happen around the end of next year, both significantly sooner than originally anticipated. The company is a clinical-stage biopharmaceutical firm developing treatments for gastrointestinal cancers and other conditions.
